Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH
4 affiliations
- 1Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, 00161 Rome, Italy
- 2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
- 3Department of Mental Health, ASL Napoli 3 Sud, 80059 Torre del Greco, Italy
- 4Department of Surgical Pathology, Medical, Molecular and Critical Area, University of Pisa, 56126 Pisa, Italy
Abstract
Serotonin syndrome (SS) and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) are well-recognized adverse drug reactions (ADRs) associated with serotonergic agents, particularly antidepressants. Although traditionally regarded as distinct clinical entities, accumulating evidence suggests that SIADH may represent a key pathophysiological link between serotonergic toxicity and acute hyponatremia, thereby explaining their frequent clinical overlap and, in some cases, severe or fatal outcomes. Excessive serotonergic activity can stimulate hypothalamic pathways regulating arginine vasopressin secretion, resulting in euvolemic hyponatremia and hyponatremic encephalopathy while simultaneously producing the characteristic neuromuscular, autonomic, and mental status abnormalities of SS. This narrative review examines the shared pathophysiological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic implications of SS and SIADH-associated hyponatremia. A comprehensive literature search was conducted, including reviews, pharmacological studies, and case reports involving antidepressants, opioids, antihistamines, nutraceuticals, and emerging serotonergic agents such as ketamine, esketamine, and psilocybin. Particular attention is given to medication combinations, over-the-counter medications, and dietary supplements that may increase serotonergic burden through pharmacodynamic and pharmacokinetic interactions. The review highlights SIADH as the “thin red line” connecting serotonergic excess with rapid-onset hyponatremia and emphasizes the diagnostic complexity arising from the overlap between neurological manifestations of SS and metabolic encephalopathy secondary to hyponatremia. It also underscores the importance of a systematic diagnostic evaluation of suspected SIADH, including assessment of serum and urinary osmolality and urinary sodium concentration. In published case reports, the absence of urinary osmolality measurements frequently precludes confirmation of SIADH according to established diagnostic criteria, limiting the diagnosis to a possible or probable form rather than a definitive one. Greater awareness of this pathophysiological interplay is essential for early recognition, accurate differential diagnosis, risk stratification, and prevention of severe outcomes through careful medication review, appropriate laboratory evaluation, electrolyte monitoring, and prompt discontinuation of offending agents.
Related
- Clinical Severity and Serotonin Toxicity in Antidepressant Self-Poisoning: Implications for Clinical Risk Assessment
- Persistent SIADH-like Hyponatremia Requiring Tolvaptan Despite Glucocorticoid Replacement in Rathke’s Cleft Cyst-Associated Hypophysitis: A Therapeutic Dilemma
- Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment.
- Comparable Acute Antidepressant-like Effects of Two Subanesthetic Ketamine Doses Are Associated with Divergent Region-Specific Molecular Responses After Adolescent Chronic Stress
- Substance Use is Not Associated with Antidepressant Response to Transcranial Magnetic Stimulation
BibTeX
@article{morena2026serotonergic,
title = {{Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH}},
author = {Donato Morena and Matteo Lippi and Letizia Biso and Federico Lucci and Emanuela Turillazzi and Vittorio Fineschi and Pasquale Scognamiglio},
journal = {Clinical Drug Investigation},
year = {2026},
month = oct,
doi = {10.1007/s40261-026-01599-z},
url = {https://doi.org/10.1007/s40261-026-01599-z},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH
AU - Donato Morena
AU - Matteo Lippi
AU - Letizia Biso
AU - Federico Lucci
AU - Emanuela Turillazzi
AU - Vittorio Fineschi
AU - Pasquale Scognamiglio
PY - 2026
DA - 2026/10/03
JO - Clinical Drug Investigation
DO - 10.1007/s40261-026-01599-z
UR - https://doi.org/10.1007/s40261-026-01599-z
AB - Serotonin syndrome (SS) and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) are well-recognized adverse drug reactions (ADRs) associated with serotonergic agents, particularly antidepressants. Although traditionally regarded as distinct clinical entities, accumulating evidence suggests that SIADH may represent a key pathophysiological link between serotonergic toxicity and acute hyponatremia, thereby explaining their frequent clinical overlap and, in some cases, severe or fatal outcomes. Excessive serotonergic activity can stimulate hypothalamic pathways regulating arginine vasopressin secretion, resulting in euvolemic hyponatremia and hyponatremic encephalopathy while simultaneously producing the characteristic neuromuscular, autonomic, and mental status abnormalities of SS. This narrative review examines the shared pathophysiological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic implications of SS and SIADH-associated hyponatremia. A comprehensive literature search was conducted, including reviews, pharmacological studies, and case reports involving antidepressants, opioids, antihistamines, nutraceuticals, and emerging serotonergic agents such as ketamine, esketamine, and psilocybin. Particular attention is given to medication combinations, over-the-counter medications, and dietary supplements that may increase serotonergic burden through pharmacodynamic and pharmacokinetic interactions. The review highlights SIADH as the “thin red line” connecting serotonergic excess with rapid-onset hyponatremia and emphasizes the diagnostic complexity arising from the overlap between neurological manifestations of SS and metabolic encephalopathy secondary to hyponatremia. It also underscores the importance of a systematic diagnostic evaluation of suspected SIADH, including assessment of serum and urinary osmolality and urinary sodium concentration. In published case reports, the absence of urinary osmolality measurements frequently precludes confirmation of SIADH according to established diagnostic criteria, limiting the diagnosis to a possible or probable form rather than a definitive one. Greater awareness of this pathophysiological interplay is essential for early recognition, accurate differential diagnosis, risk stratification, and prevention of severe outcomes through careful medication review, appropriate laboratory evaluation, electrolyte monitoring, and prompt discontinuation of offending agents.
SN - 1173-2563
SN - 1179-1918
ER -